Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3Active not recruiting 3Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Breast 1

Conditions

Breast Neoplasms 4Prostatic Neoplasms 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumour 1Recurrence 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Healthy Participants 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumours 1Advanced Solid Malignancy, 1Advanced Solid Malignancy 1Advanced Gastric Cancer 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Docetaxel 158Prednisone 131Leuprolide 95bicalutamide 86enzalutamide 83Radiotherapy 80Goserelin 80Abiraterone Acetate 76acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 54Magnetic Resonance Spectroscopy 46Zoledronic Acid 44gallium 68 PSMA-11 37Flutamide 34abiraterone 32Estramustine 32radium Ra 223 dichloride 30apalutamide 27Surveys and Questionnaires 26Gonadotropin-Releasing Hormone 26Androgen Antagonists 25cabazitaxel 24Radiosurgery 24Dutasteride 22sipuleucel-T 21Prednisolone 21Triptorelin Pamoate 20Paclitaxel 20luprolide acetate gel depot 19Radiation 19Exercise 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms × capivasertib × Clear all
NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
12 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

AstraZeneca

Phase 1 Completed
27 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02121639 2022-05-05

ProCAID

University Hospital Southampton NHS Foundation Trust

Phase 1/2 Completed
160 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡